“Our team has made excellent progress advancing our clinical programs this year, and we are eagerly anticipating the upcoming clinical results starting in December,” said Jennifer Good, President and CEO of Trevi Therapeutics (TRVI). “Positive results over the upcoming months would bring us closer to potentially addressing the significant unmet need and market opportunity in both chronic cough in IPF and RCC through Haduvio’s unique mechanism.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
- Trevi Therapeutics completes enrollment for Phase 2a RIVER trial
- Trevi Therapeutics provides update on Haduvio’s clinical development program
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
- Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress